| scholarly article | Q13442814 |
| P50 | author | Per Ljungman | Q52717443 |
| P2093 | author name string | H Wandt | |
| H Hebart | |||
| H Einsele | |||
| T Klingebiel | |||
| T Mayer | |||
| K Schaefer-Eckart | |||
| O Ringden | |||
| J Loeffler | |||
| H J Dornbusch | |||
| C Engel | |||
| N Stenger | |||
| C Meisner | |||
| J Tollemar | |||
| L Klingspor | |||
| P2860 | cites work | Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome | Q28276727 |
| Aspergillosis case-fatality rate: systematic review of the literature | Q31918085 | ||
| Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group | Q33854646 | ||
| Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study | Q33983629 | ||
| Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. | Q34455633 | ||
| Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients | Q34553509 | ||
| Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis | Q34719835 | ||
| Specific infectious complications after stem cell transplantation | Q35200641 | ||
| Detection of Aspergillus DNA in cerebrospinal fluid from patients with cerebral aspergillosis by a nested PCR assay | Q35220840 | ||
| Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ | Q37164067 | ||
| Circulating Candida antigens and antibodies: useful markers of candidemia. | Q40189009 | ||
| Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study | Q40497134 | ||
| Aspergillus fungemia: report of two cases and review | Q40529514 | ||
| Prospective screening by a panfungal polymerase chain reaction assay in patients at risk for fungal infections: implications for the management of febrile neutropenia | Q40610610 | ||
| A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients | Q40645972 | ||
| Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis | Q43441503 | ||
| Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients | Q50161899 | ||
| Molecular detection and identification of Candida and Aspergillus spp. from clinical samples using real-time PCR. | Q51187020 | ||
| Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. | Q54619719 | ||
| Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients | Q72695714 | ||
| Serum D-arabinitol measured by automated quantitative enzymatic assay for detection and therapeutic monitoring of experimental disseminated candidiasis: correlation with tissue concentrations of Candida albicans | Q72817726 | ||
| Detection of PCR-amplified fungal DNA by using a PCR-ELISA system | Q74602155 | ||
| Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC) | Q78144262 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| amphotericin B | Q412223 | ||
| P304 | page(s) | 553-561 | |
| P577 | publication date | 2008-12-15 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. | |
| P478 | volume | 43 |
| Q38049498 | A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Gruppo Italiano Malattie Ematologiche dell'Adulto, Gruppo Italiano Trapianto di Midollo Osseo, As |
| Q37983106 | A practical critique of antifungal treatment guidelines for haemato-oncologists. |
| Q37918556 | Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations |
| Q51057692 | Advances and prospects for molecular diagnostics of fungal infections. |
| Q38082740 | Advancing the Field: Evidence for New Management Strategies in Invasive Fungal Infections |
| Q54394711 | An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. |
| Q40886644 | Analysis of the efficiency and costs of antifungal prophylaxis and mycological diagnostics in patients undergoing allogeneic haematopoietic cell transplantation: "real life" evaluation |
| Q28080147 | Antifungal Therapy in Hematopoietic Stem Cell Transplant Recipients |
| Q38944746 | Antifungal stewardship considerations for adults and pediatrics |
| Q49567812 | Bacterial sepsis : Diagnostics and calculated antibiotic therapy |
| Q49589601 | Bacterial sepsis : Diagnostics and calculated antibiotic therapy |
| Q37480190 | Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species |
| Q40063394 | Clinical considerations in the early treatment of invasive mould infections and disease. |
| Q51617424 | Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. |
| Q35678982 | Combining standard clinical methods with PCR showed improved diagnosis of invasive pulmonary aspergillosis in patients with hematological malignancies and prolonged neutropenia |
| Q38284458 | Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014. |
| Q37401327 | D-index: A New Scoring System in Febrile Neutropenic Patients for Predicting Invasive Fungal Infections |
| Q37833638 | Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies |
| Q37823011 | Detection and investigation of invasive mould disease |
| Q36620870 | Detection of Airway Colonization by Aspergillus fumigatus by Use of Electronic Nose Technology in Patients with Cystic Fibrosis |
| Q38079194 | Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B. |
| Q37777195 | Diagnosis of invasive fungal infections in immunocompromised children |
| Q36584898 | Diagnostic methods for invasive fungal diseases in patients with hematologic malignancies |
| Q38723910 | Diagnostics and susceptibility testing in Aspergillus |
| Q37934487 | ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients |
| Q40629298 | Economic analysis of empiric versus diagnostic-driven strategies for immunocompromised patients with suspected fungal infections in the People's Republic of China |
| Q40174281 | Economic evaluation of a preemptive treatment strategy for invasive fungal infection in neutropenic patients with hematological diseases |
| Q40241548 | Empirical amphotericin B therapy on day 4 or day 8 of febrile neutropenia |
| Q38165198 | Enhancing molecular approaches for diagnosis of fungal infections |
| Q46050924 | European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update |
| Q39275780 | Evaluating the use of PCR for diagnosing invasive aspergillosis |
| Q34430579 | Evaluation of a polymerase chain reaction assay for pathogen detection in septic patients under routine condition: an observational study. |
| Q38103680 | Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial |
| Q37220711 | Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America |
| Q43430861 | Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation |
| Q37287794 | Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome |
| Q39196802 | Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use. |
| Q48295098 | Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation |
| Q26778187 | Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia |
| Q37363385 | Molecular Diagnostic Testing for Aspergillus |
| Q38286512 | Molecular diagnosis of sepsis: New aspects and recent developments |
| Q34303687 | New approaches to sepsis: molecular diagnostics and biomarkers. |
| Q34532546 | Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America |
| Q37780756 | Primary diagnostic approaches of invasive aspergillosis--molecular testing |
| Q38171058 | Rapid diagnosis of sepsis |
| Q64962326 | Strengthening the One Health Agenda: The Role of Molecular Epidemiology in Aspergillus Threat Management. |
| Q97542220 | The current state of antifungal stewardship among pediatric antimicrobial stewardship programs |
| Q35193749 | The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. |
| Q37469829 | Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). |
| Q38263489 | Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients |
| Q37785548 | Updated guidelines for managing fungal diseases in hematology patients |
| Q36364856 | Use of antifungal drugs in hematology |
| Q33451077 | Usefulness of biological markers in the diagnosis of invasive candidiasis |
| Q41860895 | Why is biopsy of suspected fungal lung lesions necessary? |
| Q37875790 | Will polymerase chain reaction (PCR)-based diagnostics improve outcome in septic patients? A clinical view |
| Q88739460 | [The clinical value of diagnostic-driven therapy of invasive fungal disease (IFD) type unclassified CⅡgroup in multiple myeloma patients during inducing chemotherapy] |
Search more.